Aura Biosciences, Inc.
News
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Globe Newswire Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders...\n more…
Aura Biosciences (NASDAQ:AURA) Lifted to Strong-Buy at Lifesci Capital
Ticker Report Lifesci Capital upgraded shares of Aura Biosciences (NASDAQ:AURA - Free Report) to a strong-buy rating in a research note released on Monday, Zacks.com reports. Several other equities analysts also...\n more…
We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely
Simply Wall St There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...\n more…
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024
Globe Newswire Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic OncologyBOSTON, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a...\n more…
Aura Biosciences (NASDAQ:AURA) Rating Reiterated by JMP Securities
Ticker Report Aura Biosciences (NASDAQ:AURA - Get Free Report)s stock had its "market outperform" rating restated by research analysts at JMP Securities in a research note issued on Wednesday, Benzinga...\n more…